Asset Details
Do you wish to reserve the book?
Colchicine reduces neointima formation and VSMC phenotype transition by modulating SRF-MYOCD activation and autophagy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Colchicine reduces neointima formation and VSMC phenotype transition by modulating SRF-MYOCD activation and autophagy
Do you wish to request the book?
Colchicine reduces neointima formation and VSMC phenotype transition by modulating SRF-MYOCD activation and autophagy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Colchicine reduces neointima formation and VSMC phenotype transition by modulating SRF-MYOCD activation and autophagy
2025
Overview
Vascular smooth muscle cell (VSMC) phenotype transformation significantly contributes to vascular intimal hyperplasia. However, effective preventive and therapeutic measures are lacking. Colchicine, a binary alkaloid derived from
Colchicum autumnale
, is traditionally used for treating inflammatory diseases. Its role in neointima formation is not fully understood. Here, we investigated the role of colchicine in vascular intimal hyperplasia. We found that colchicine significantly reduced vascular intimal hyperplasia in an animal model at 7, 14, and 28 days post carotid artery ligation and increased the number of contractile-phenotype VSMCs (SMA-positive cells) in the neointimal areas. In vitro experiments demonstrated that colchicine facilitated the transition of VSMCs from a proliferative phenotype to a contractile phenotype. Additionally, colchicine attenuated PDGF-BB-induced phenotypic conversion and upregulated the expression of serum response factor (SRF) and myocardin (MYOCD). Further molecular mechanistic studies revealed that colchicine inhibited the expression of forkhead box protein O3A (FOXO3A) to increase the activation of the SRF‒MYOCD complex. FOXO3A can bind to MSX1/2, thereby inhibiting the expression of SRF–MYOCD and contractile genes. Moreover, colchicine maintains vascular homeostasis and stabilizes the contractile phenotype by affecting the expression of autophagy-related genes (LC3II, p62, and Beclin-1) induced by FOXO3A. Additionally, colchicine inhibited monocyte/macrophage infiltration and inflammatory cytokine expression. In summary, this study suggests that colchicine inhibits vascular intimal hyperplasia by modulating FOXO3A-mediated SRF-MYOCD activation and autophagy, providing new insights for future therapeutic approaches targeting occlusive vascular diseases.
Publisher
Springer Nature Singapore,Nature Publishing Group
Subject
/ Animals
/ Biomedical and Life Sciences
/ Forkhead Box Protein O3 - metabolism
/ Kinases
/ Male
/ Mice
/ Muscle, Smooth, Vascular - drug effects
/ Muscle, Smooth, Vascular - metabolism
/ Myocytes, Smooth Muscle - drug effects
/ Myocytes, Smooth Muscle - metabolism
/ Nuclear Proteins - metabolism
/ Platelet-derived growth factor
/ Platelet-derived growth factor BB
/ Proteins
/ Serum Response Factor - metabolism
/ Trans-Activators - metabolism
/ Vaccine
